The international, randomized phase 3 HD15 trial established 6xeBEACOPP as standard therapy for patients with newly diagnosed advanced-stage Hodgkin lymphoma (HL) within the German Hodgkin Study Group (GHSG). We performed a follow-up analysis to assess long-term efficacy and safety of this approach. Between 2003 and 2008, 2182 patients aged 18 to 60 years were recruited and randomized in a 1:1:1 ratio between 8 or 6 cycles of eBEACOPP or 8 cycles of the dose-dense BEACOPP-14 regimen, each followed by 30 Gy radiotherapy in case of positron emission tomography (PET)-positive residual lesions ≥2.5 cm. The study aimed at demonstrating non-inferiority regarding efficacy of the 2 experimental arms on a significance level of 2.5% each. The intention-to-treat analysis comprised 2126 patients with a median follow-up of 102 months. Ten-year progression-free survival was 81% (97.5% CI 77-85) with 8xeBEACOPP, 84% (80-87) with 6xeBEACOPP, and 84% (80-87) with 8xBEACOPP-14; the non-inferiority margin of 1.51 for the hazard ratio (HR) could be excluded for both comparisons (6xeBEACOPP, HR = 0.7, 97.5% CI 0.5-1.0; 8xBEACOPP-14, HR = 0.9, 97.5% CI 0.7-1.2). Overall survival at 10 years was 88% (85-91), 90% (88-93), and 92% (89-94), respectively. A total of 142 second malignancies corresponding to 10-year cumulative incidences of 10%, 7%, and 7% and standardized incidence ratios of 4.3, 2.5, and 2.8 were reported for 8xeBEACOPP, 6xeBEACOPP, and 8xBEACOPP-14, respectively. This updated analysis of the HD15 trial thus confirms the efficacy and reports on the long-term safety of a shortened first-line chemotherapy consisting of 6xeBEACOPP followed by PET-guided radiotherapy in advanced-stage HL.

3rd Medical Department Paracelsus Medical University and Salzburg Cancer Research Institute Salzburg Austria

Berlin Reference Center for Lymphoma and Haematopathology Berlin Germany

Department of Internal Medicine Haemato Oncology University Hospital and Faculty of Medicine of Masaryk University Brno Czech Republic

Department of Internal Medicine Hematology University Hospital Kralovske Vinohrady 3rd Faculty of Medicine Charles University Prague Czech Republic

Department of Medical Oncology University Hospital Inselspital Bern Switzerland

Department of Nuclear Medicine University Hospital of Cologne Cologne Germany

Department of Radiotherapy University Hospital of Muenster Muenster Germany

German Hodgkin Study Group Department of Internal Medicine 1 University Hospital of Cologne Cologne Germany

Salzburg Cancer Research Institute and AGMT Salzburg Austria

Swiss Group for Clinical Cancer Research Bern Switzerland

University of Heidelberg Heidelberg Germany

University of Tübingen Tübingen Germany

VU University Medical Center Amsterdam The Netherlands

Zobrazit více v PubMed

Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478–1484. PubMed

Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013;31:684–691. PubMed PMC

Diehl V, Franklin J, Pfreundschuh M, et al. German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386–2395. PubMed

Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011;29:4234–4242. PubMed

Engert A, Haverkamp H, Kobe C, et al. German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012;379:1791–1799. PubMed

Age and sex standardized incidence rates 2013, Association of Population-based Cancer Registries in Germany (GEKID), www.gekid.de.

Life tables 2013/2015, Federal Statistical Office (DESTATIS), 2017, www.destatis.de.

Juweid ME, Stroobants S, Hoekstra OS, et al. Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571–578. PubMed

Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med 2016;374:2419–2429. PubMed PMC

Borchmann P, Görgen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin. Lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2017. PubMed

Borchmann P, Haverkamp H, Lohri A, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP escalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol 2017;18:454–463. PubMed

Provencio M, Salas C, Millán I, et al. Late relapses in Hodgkin lymphoma: a clinical and immunohistochemistry study. Leuk Lymphoma 2010;51:1686–1691. PubMed

Bodis S, Henry-Amar M, Bosq J, et al. Late relapse in early-stage Hodgkin's disease patients enrolled on European Organization for Research and Treatment of Cancer protocols. J Clin Oncol 1993;11:225–232. PubMed

Meyer RM, Gospodarowicz MK, Connors JM, et al. NCIC Clinical Trials Group; Eastern Cooperative Oncology Group. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 2012;366:399–408. PubMed PMC

Sasse S, Bröckelmann PJ, Görgen H, et al. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the GHSG HD7, HD8, HD10 and HD11 trials. J Clin Oncol 2017;35:1999–2007. PubMed

Bröckelmann PJ, Görgen H, Kohnhorst C, et al. Late relapse of classical hodgkin lymphoma: an analysis of the German Hodgkin Study Group HD7 to HD12 trials. J Clin Oncol 2017;35:1444–1450. PubMed

Schaapveld M, Aleman BM, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. N Engl J Med 2015;373:2499–2511. PubMed

Engert A, Younes A (eds). Hodgkin Lymphoma: A Comprehensive Overview. Chapter 24: Hodgson DC, van Leeuwen FE. Second Malignancy Risk After Treatment of Hodgkin Lymphoma. 375–409. Springer International Publishing 2015.

Travis LB, Demark Wahnefried W, Allan JM, et al. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 2013;10:289–301. PubMed

van Eggermond AM, Schaapveld M, Lugtenburg PJ, et al. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma. Blood 2014;124:319–327. PubMed

Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005;23:7614–7620. PubMed

Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878–1886. PubMed

Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007;99:206–214. PubMed

Kreissl S, Müller H, Görgen H, et al. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: A longitudinal study of the German Hodgkin Study Group. Lancet Oncol 2016;17:1453–1462. PubMed

Behringer K, Görgen H, Müller H, et al. on behalf of the German Hodgkin Study Group. Cancer-related fatigue in patients with and survivors of Hodgkin Lymphoma: the impact on treatment outcome and social reintegration. J Clin Oncol 2016;34:4329–4337. PubMed

Eichenauer DA, Thielen I, Haverkamp H, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2014;123:1658–1664. PubMed

Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016;17:1283–1294. PubMed PMC

Chen R, Zinzani PL, Fanale MA, et al. KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35:2125–2132. PubMed PMC